NeuroPhage Selected as Top 10 CNS Biotech Company at the Upcoming 6th Annual Therapeutics Area Partnerships Conference

CAMBRIDGE, MA – November 16, 2011 – NeuroPhage Pharmaceuticals today announced it has been selected one of the Top 10 CNS companies worldwide to present at the 6th Annual Therapeutics Area Partnerships Conference scheduled for December 1st and 2nd and to be held in Boston. The Company’s presentation will be made on December 1, 2011 in the “Top 10 Projects to Watch” track. The Company plans to provide a brief update on its novel technology that addresses protein aggregation diseases.

About NeuroPhage

NeuroPhage is a biotechnology company focusing on a unique disease-modifying phage approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a Cambridge-based team, together with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. NeuroPhage has raised $19.5M since inception from Shire LLC, Mérieux Développement and undisclosed private investors.


Media Contact
Sarah Sutton
Ten Bridge Communications